Semaglutide

Regulatory status

Copies of commercially available approved drugs. Compounding is restricted under sections 503A and 503B outside a declared shortage. Quoted only on request to verified facilities, who are responsible for confirming their own eligibility.

Summary

Semaglutide is a long-acting GLP-1 receptor agonist consisting of a 31-residue backbone with an aminoisobutyric acid substitution and a C18 fatty diacid side chain conjugated through a linker. It is one of the most analytically demanding molecules in this catalogue.

The side chain conjugation is where lots differ most. Unacylated backbone, over-acylated species and linker-only adducts all appear in material that reports high reversed-phase purity, so we require a full impurity table rather than a single figure.

Typical related substances

Typical related substances are the unacylated backbone, di-acylated species, linker hydrolysis products and des-amino variants.

Regulatory note

Copy of a commercially available approved drug. Compounding is restricted under sections 503A and 503B outside a declared shortage.

Regulatory status shown is our current understanding and is not legal advice. Each facility is responsible for confirming eligibility for its own licence type before purchase.